【摘要】 目的研究晚期胃癌患者血清PECAM-1和IGF-1表达水平与临床病理特征及预后的相关性。方法运用酶联免疫法(ELISA法)检测晚期胃癌患者治疗前外周血中PECAM-1、IGF-1的表达水平,以此分析晚期胃癌预后与外周血中PECAM-1、IGF-1蛋白表达水平的关系,及与临床基本信息、病理特征的关系。结果①共入组患者18例。中位总生存时间(m OS)460 d。②男性与女性患者之间、老年与非老年患者之间、腺癌与印戒细胞癌患者之间、既往是否行胃癌根治术,PECAM-1和IGF-1水平差异均无统计学意义。③存活患者与死亡患者IGF-1平均值差异无统计学意义(P=0.780)。存活患者与死亡患者PECAM-1平均值差异有统计学意义(P=0.050)。④按PECAM-1平均值分成2组(PECAM-1高浓度组、PECAM-1低浓度组),并比较2组总生存(OS)的差异。结果表明,PECAM-1高浓度组的OS显著短于PECAM-1低浓度组(283 d vs.484 d,P=0.035)。⑤按IGF-1平均值分成2组(IGF-1高浓度组、IGF-1低浓度组),并比较2组OS差异。IGF-1高浓度组的OS显著短于IGF-1低浓度组(226 d vs.357 d,P=0.030)。结论①晚期胃癌患者PECAM-1和IGF-1表达水平与临床病例特征无显著相关性。②晚期胃癌患者血清PECAM-1、IGF-1的浓度和患者的预后及生存期是有关的。当患者血清的PECAM-1和IGF-1浓度较高时,患者预后差,生存期短。更多还原

【Abstract】 Objective To analyze the relationship between serum PECAM-1 and IGF-1 levels and the clinical significance and prognosis of patients with advanced gastric cancer. Methods The serum levels of PECAM-1 and IGF of 18 patients with advanced gastric cancer were detected by using ELISA before chemotherapy. T-test comparison was used to analyze the correlation between serum PECAM-1 and IGF-1 levels and clinicopathologic feature and survival. Results① Among the 18 patients. The median overall survival time(m OS) was 460 days.② There was no significant difference between serum PECAM-1 and IGF-1 expression levels and clinicopathologic feature, including gender( men and women),age( > 60 years and < 60 years),pathological type( adenocarcinoma or Signet ring cell carcinoma),and previous radical gastrectomy.③ No statistically significant difference between the serum mean concentrations of IGF-1 in these died and alive patients( P = 0. 780). The mean PECAM-1 value between survivors and the dead patients,approaching statistical differences( P = 0. 050).④ According to the average level of PECAM-1,patients were divided into two groups( PECAM-1 high group,PECAM-1 low group). The results show that the m OS of the PECAM-1 high group was283 days,significantly shorter than PECAM-1 low group,which was 484 days,P = 0. 035.⑤ According to the average level of IGF-1,patients were divided into two groups( IGF-1 high group,IGF-1 low group). Similarly,the m OS of the IGF-1 high group was 226 days,significantly shorter than IGF-1 low group,which was 357 days( P = 0. 030). Conclusion① Here is no correlation between serum PECAM-1 and IGF-1 expression levels and clinicopathologic feature in advanced gastric cancer patients.② He serum PECAM-1 and IGF-1 expression levels are related to the patient’s prognosis and survival in advanced gastric cancer patients. The prognosis and survival is adversely affected in patients with high serum PECAM-1 and IGF-1 concentrations.更多还原